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CRISPR-mediated genome editing has undoubtedly revolutionized genetic engineering of 
animals. With the ability for virtually unlimited modification of almost any genome it is easy 
to forget which amazing discoveries paved the way for this groundbreaking technology. Here, 
we summarize the history of genome editing platforms, starting from enhanced integration of 
foreign DNA by meganuclease-mediated double strand breaks to CRISPR/Cas9, the leading 





Genetic engineering of organisms is the key to biomedical and biotechnological 
research. The ultimate tool would allow precise and unlimited modification of any given nucleic 
acid sequence in a simple fashion. With the rise of genome editing we have never been closer 
to accomplishing this goal. This review will summarize the exciting key developments leading 
to the breakthrough of genome editing with a particular focus on CRISPR-based tools as the 
leading technology to date. 
Genetic engineering started with transgenesis, the deliberate transfer of genetic 
information from one organism to another. In 1974, Rudolf Jaenisch demonstrated that viral 
DNA injected into blastocysts led to stable integration in the genome of mice1. This is 
considered to be the first transgenic animal generated. The term “transgenic” though was 
introduced only in 1981 by Gordon and Ruddle when they and others showed that injection of 
DNA into pronuclei of murine zygotes conferred stable germline transmission of the genetic 
modification to the next generation2-5. Although integration occurred randomly and without 
copy number control, researchers were able to establish a stable genetically engineered mouse 
 3 
line for the first time. At the same time, two groups independently isolated pluripotent mouse 
embryonic stem cells (ESC)6, 7 which were able to colonize the entire embryo, including the 
germ line, upon injection into host blastocysts8. In these cells, Oliver Smithies and Mario 
Capecchi employed the process of homologous recombination to inactivate a specific gene in 
the mouse9, 10. This groundbreaking discovery, termed gene targeting, allowed site-directed 
modification of the genome for the first time and earned Mario Capecchi, Martin Evans and 
Oliver Smithies the 2007 Nobel Prize in Physiology or Medicine. By the additional coupling 
with a site-specific recombination system (i.e. Cre-lox), the group of Klaus Rajewsky expanded 
the scope of gene targeting in a time and cell type specific fashion and this approach soon 
became the gold standard for genome engineering in mice for the next decades11, 12. Despite its 
undeniable power, the homologous recombination approach exhibited several limitations. 
Firstly, the poor integration frequency at a specific site in zygotes required the time-consuming 
detour though ESC targeting and subsequent injection into blastocyst for the generation of 
genetically modified (GM) mice13. Secondly, due to the low integration frequency, a selectable 
marker (often an antibiotic resistance gene) was required to determine which ESCs integrated 
the DNA.  The use of this marker would leave undesired genetic material that required 
subsequent removal to avoid altering expression of the gene9, 10. Finally, the approach was 
largely limited to mice due to the lack of protocols for ESC isolation or the failure to isolate 
such cells in most other species14. 
 
 
The rise of genome editing (1985 – 2013) 
 
How could these limitations be overcome? One important step was the discovery that 
double strand breaks (DSB) dramatically enhance the integration of foreign DNA in 
mammalian cells15-17. These studies employed the meganuclease I-SceI to induce DSB in the 
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genome of mouse cells. DSBs subsequently recruit the endogenous repair machinery and are 
either repaired by end joining pathways, which can result in random insertions and deletions 
(INDELs) or, if a DNA repair template is provided, by homology-directed repair (HDR) 
pathways (Figure 1). Meganucleases are low frequency cutters with a recognition sequence of 
typically 20-30 bp discovered in yeast in 198518 (Figure 2). They are involved in gene 
conversion processes like duplication and have now been identified in many microbial 
genomes19. Although hundreds of naturally occurring meganucleases exist, their fixed 
recognition sequence drastically limited the choice of targetable loci. Subsequent re-
engineering of the DNA recognition site led to more flexibility and enabled site directed 
genome modification in mammalian cells, mice and rats20-22. Yet, reconfiguring the structure 
of an entire protein for every single target site was tedious.   
What if there was a protein motif which has already naturally evolved to bind various 
different nucleotide sequences? Zinc fingers are small protein motifs with sequence specific 
DNA binding capacity. They were first discovered in 1985 as part of a transcription factor in 
frog oocytes but are in fact present in many species, including humans23, 24. They were termed 
zinc fingers as they are stabilized by a zinc ion in order to bind their DNA target. In contrast to 
other DNA binding motifs, they utilize a cascade of modules in which a few key residues in the 
protein mediate recognition. Each module harbors a DNA binding motif specific to three 
consecutive base pairs of the target sequence. This modular structure makes them highly 
versatile in binding specific DNA sequences of various lengths24. In 1996, researchers fused 
these zinc finger modules to the DNA cleavage domain of the restriction enzyme FokI in order 
to generate a programmable nuclease, termed Zinc Finger Nucleases (ZFN)25. The ease of 
inducting DSB by ZFN subsequently led to a number of applications in biotechnology and 
biomedicine. Pilot experiments in 2001 in Xenopus oocytes demonstrated the feasibility of 
enhanced HDR by ZFN26. Shortly thereafter, the approach was optimized and applied to other 
organisms, like Drosophila and human cells, and also employed therapeutically to correct the 
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human SCID mutation in vitro27-29. The latter study introduced the term “genome editing” in 
2005 for the first time as an analogy to word processing29, 30.  
DSB, like those caused by ZFNs, can be repaired by HDR if a repair template is 
provided. That was how Knock-Out (KO) and Knock-In (KI) mutations have been generated 
with genome editing. However, most DSB in vertebrate cells are repaired by error-prone end 
joining pathways which frequently result in INDELs and not by HDR. Inspired by previous 
work in lower organisms like flies, worms and plants, in 2008 three independent groups realized 
that one can utilize the thus far undesired INDEL mechanism to efficiently induce KOs in 
zebrafish and mammalian cells without the need of HDR with a repair template. This process 
was so efficient that no selection was needed31-33. A break-through for the generation of GM 
mammals came in 2009 when it was shown that microinjection of DNA or mRNA encoding 
for specific ZFNs in rat zygotes produced the first KO rats34. This technology was swiftly 
adapted to generate GM model organisms like mice and rabbits but also livestock animals like 
cattle and pigs (see Table S1 online for references).  
 Another major discovery in the field of designer nucleases arose with the construction 
of TALENs in 201035, 36. Researchers realized that the DNA binding domain of ZFN can be 
exchanged with more flexible and easier to generate DNA binding modules. These modules 
originated from Transcription Activator–Like Effector (TALE) proteins discovered in plant 
pathogenic bacteria of the genus Xanthomonas. These bacteria utilize the sequence specific 
binding capacity of TALEs to manipulate the gene expression of the infected plant cell in their 
favor. Like zinc finger proteins TALEs possess a variable DNA binding domain. However, 
there is a simple code of recognition where one module in the protein corresponds to only one 
of the four nucleotides (A, T, C or G). Various combinations of these four modules can therefore 
target any DNA sequence. Furthermore, as only two amino acids are responsible for the 
nucleotide specificity, TALEs are easier to generate than are zinc finger proteins37. For genome 
editing, TALE Nucleases (TALEN) stem from the fusion of a sequence-tailored TALE DNA-
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binding domain to the FokI endonuclease domain (analogous to that used for ZFN)35, 36. As the 
design and the generation of TALENs required less effort and was more flexible, they 
immediately started to replace ZFN for genome editing. Soon after their first application in cell 
culture, TALENs were used to modify the genomes of a number of model organisms including 
worms, zebrafish, frogs, rats, mice and rabbits. But they were also employed in live-stock like 
pigs, goats, sheep and cattle as well as non-human primates (see Table S1 online for references). 
 
 
The history of CRISPR genome editing (1987 – 2013) 
 
What if there was a protein which has programmable DNA binding capabilities like 
TALE and zinc finger proteins but does not need time consuming construction of a new protein 
domain? Ideally, this protein would already even exist as a nuclease in nature. Unknowingly, 
such a system had already been discovered, one we now know as the CRISPR/Cas system in 
bacteria. 
In the late 1980s, repeats were observed in the genome of Escherichia coli which, unlike 
typical tandem repeats, were separated by non-repeating spacer sequences38. The nature of these 
repeats remained elusive for more than a decade until improved sequencing technologies 
enabled the decoding of many other genomes. In 2000, Mojica and co-workers realized that 
these repeats are present in many other bacteria and virtually all archaea, which pointed to an 
important role for these elements39. In addition, these repeats were shown to be associated with 
conserved genes subsequently called CRISPR-associated or Cas genes, which are in fact 
naturally occurring endonucleases. This was also the first use of the term CRISPR for Clustered 
Regularly Interspaced Short Palindromic Repeats40. In 2005, three research groups 
independently demonstrated that the spacer sequences are identical to genomes from phages 
and other foreign genetic elements41-43. In 2007, the nature of CRISPR was finally proven, when 
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Horvath and co-workers demonstrated that infected bacteria incorporate spacers derived from 
phage which in turn directs the Cas protein to the genome of the invaders where it precisely 
cuts the phage DNA. The CRISPR/Cas system therefore provides a defense mechanism against 
infections, similar to the adaptive immune response known from higher organisms like 
mammals44. Soon after it became clear that so-called CRISPR RNA (crRNA) is transcribed 
from the spacer to guide the Cas protein to its target45 and that the target is DNA46. A short 
sequence motif adjacent to the crRNA targeted sequence on the target DNA, termed the 
protospacer adjacent motif (PAM), was not only shown to be critical for cleavage but also 
responsible for self vs. non-self discrimination of the CRISPR system47-50. In addition, it was 
shown that in a certain CRISPR system only a single Cas protein, that is Cas9, confers DNA 
cleavage49, 51 and trans-activating crRNAs (tracrRNAs), which play a role in the maturation of 
crRNA, are critical for its activity52. Undoubtedly, the most important experiments were 
conducted independently by the group of Emmanuelle Charpentier in collaboration with 
Jennifer Doudna and almost in parallel by the group of Virginijus Siksnys. They demonstrated 
that the CRISPR/Cas9 system can be reconstituted in vitro and programmed to target desired 
sequences in other species which proved its applicability as a programmable nuclease for 
genome editing49, 53. Charpentier and Doudna, in conjunction with Martin Jinek, also simplified 
the system when they fused the crRNA and tracrRNA into a single guide RNA (sgRNA) which 
retained full activity49. Immediately thereafter, groundbreaking studies from the Doudna group 
in parallel with the group of Feng Zhang and George Church adapted the CRISPR/Cas9 system 
for in vivo genome editing in mammalian cells54-56. Soon after CRISPR/Cas9 was used by the 
Jaenisch group to generate mice with multiple KO, conditional KO and reporter genes by zygote 
injection57, 58.  
Thus, instead of constant target specific re-engineering of protein modules as needed 
for ZFNs and TALENs, the Cas9 endonuclease requires only the simple construction of a short 
RNA molecule for genome editing at a given locus. In addition to its simple low-cost design 
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this approach can also swiftly be multiplexed to target multiple genes at the same time. As this 
system was easy to adapt by any biomedical laboratory, CRISPR genome editing revolutionized 
the field and subsequently Emmanuelle Charpentier and Jennifer Doudna were awarded the 
2020 Nobel Prize in Chemistry for its discovery. To date, this technology has been used to 
modify the genome of virtually all model organisms including fly, worm, zebrafish, frogs, rat, 
rabbit, pig, cattle, goat, sheep and non-human primates (see Table S1 online for references). 
 
Figure 1. Mechanism of major genome editing platforms.  
All four major genome editing systems lead to DSBs at the desired locus. These DSBs breaks are either 
repaired by error-prone end-joining pathways resulting in INDELs or, if a DNA repair template is 
provided, by HDR. The latter mechanism can be exploited to introduce site-specific mutations into the 
locus of interest. While meganucleases, ZFN and TALENs rely on protein-DNA interaction for target 
recognition CRISPR/Cas9 utilizes a dual guide RNA composed of a generic tracrRNA and a specific 
crRNA.  
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Natural and engineered CRISPR systems (2013 – now) 
 
The Cas9 of Streptococcus pyogenes (SpCas9) used in the original publication has a 
simple PAM requirement (NGG) and CRISPR/Cas9 is still by far the most popular 
programmable Cas nuclease system for genome editing. Nevertheless, researchers have 
constantly searched for other Cas9 or Cas9-like proteins and developed a number of engineered 
versions of Cas9 with different properties like alternative PAM requirements, protein size, or 
substrate specificity to harness them for genome editing59.  
In vivo mutagenesis of specific organs in adult animals as well as gene therapy in 
humans is most often accomplished by means of viral vectors. The large protein size of SpCas9 
(about 1400 amino acids), however, does not allow for delivery using the popular adeno-
associated virus system. In search for a smaller Cas9 variants, researchers discovered in 2015 
that Staphylococcus aureus utilizes a much smaller Cas9 (about 1000 amino acids). This 
allowed genome editing in specific organs in mice by viral delivery of CRISPR/Cas960. Many 
other Cas proteins have followed which differ in their protein size, PAM requirement, spacer 
length and editing specificity. With Cas12a, initially termed Cpf1, an entirely new class of 
CRISPR proteins was introduced in 201561. This system broadened the applicability of genome 
editing to TT rich PAM targets as Cas12a uses the PAM sequence TTTV (V equals A, G or C). 
Only one year later, it was shown to work in vivo by the production of KO mice62, 63. Previously 
inaccessible loci could now be edited with this system. Whereas all known CRISPR system 
until this point targeted DNA, the group of Feng Zhang discovered the CRISPR/Cas13 system, 
an RNA editing system, in 201764. By targeting RNA, CRISPR/Cas13 can be used to modify 
the function of a gene by degradation of the mRNA allowing the reduction of a genes function 
by knock-down instead of a complete removal. Cas13 orthologs have recently also been shown 
to be effective in vivo in several animal embryos including zebrafish and mice65. 
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Apart from harnessing natural Cas proteins, researchers have started to re-engineer the 
well-characterized Cas9 to develop new variants. These efforts pursued mainly two goals: 
broadening the range of targetable site by changing PAM specificities and enhancing the 
fidelity of Cas9. One disadvantage of the CRISPR system are off-target modifications which 
represent undesired mutations at loci that resemble the on-target sequence. It has been shown 
that SpCas9 can tolerate several mismatches depending on their distribution and position in the 
guide sequence66. Off-target mutations during genome editing in animals with a short 
generation cycle like mice is undesirable but can be partially compensated by backcrossing to 
remove the unwanted mutation. In contrast, off-targets in long-lived animals, like most live 
stock, and especially during therapeutic intervention in humans must be avoided. Therefore, 
researchers are still researching for ways to increase the specificity of Cas9. In a first attempt, 
the Cas9 protein has been used as a tandem, much like ZFNs and TALENs before. To this end 
one of the two nuclease domains of Cas9 was inactivated leading to a nickase which cuts only 
one strand of DNA. This approach proved to increase the specificity of the system in vitro and 
in vivo in mice67. The first high-fidelity protein variant of Cas9 was generated three years later 
in 2016 by Feng Zhang’s group. They used structure-guided engineering in order to change 
residues in the protein to prevent nonspecific DNA binding68. Currently, many more variants 
have been created which can discriminate even single base pair mismatches69. However, none 
of these versions seem to retain the on-target activity of wild-type SpCas970. Another limitation 
of the CRISPR system for genome editing is the requirement of a PAM sequence like NGG for 
SpCas9. This limits the targeting scope of Cas9 resulting in inaccessibility of certain loci. The 
first Cas9 with an altered and simplified PAM to overcome this limitation was introduced in 
2015 by J. Keith Joung’s group71. This work, performed in zebrafish and human cells, 
demonstrated that a re-engineered SpCas9 efficiently recognized alternative PAM sequences 
like NGA. To date re-engineered Cas9 variants can recognize a variety of PAM sequences. 
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Most recently, a variant with near PAMless activity was constructed although this increased 
flexibility unfortunately still affects on-target activity72.  
 Another risk of genome editing with nucleases like Cas9 are the undesired effects of 
DNA DSBs. Although these DSBs facilitate the introduction of foreign DNA they can also lead 
to undesired DNA modifications and even re-arrangements within the genome which must be 
avoided, especially in long-lived animals and precision human medicine. To circumvent DNA 
DSBs, the group of David Liu introduced base editing in 201673. Here, a catalytically 
inactivated Cas9 is fused to a deaminase enzyme domain. This system allows single-base pair 
conversion of specific nucleotides, like C to T, without a DSB and without relying on HDR 
using donor templates. Base editing has now been used in many model organisms like zebrafish, 
frogs, mice, rats and rabbit but also in live-stock like pigs, goat and sheep and non-human 
primates (see Table S1 online for references). 
Base editors can only convert certain nucleotides and cannot introduce deletions or 
insertions. To overcome these limitations another exciting CRISPR application was introduced 
in 201974. Prime editing makes use of a Cas9 nickase fused to a reverse transcriptase. A dual 
functional prime editor gRNA (pegRNA) guides the Cas9 nickase to the desired locus. In 
addition, the pegRNA also harbors the template for the reverse transcriptase to copy the 
intended genetic change into the target DNA, starting from a short primer binding site 
complementary to the second strand of the target DNA. This system can install specific INDELs 
and all base-to-base conversions without relying on HDR and DNA DSB. Initially developed 
in vitro, this system has already proven to be applicable to model organisms like mice75. Prime 
editing holds great promises for precise modification in animals and has clinical potential for 
human health as it shows exceptionally high specificity. 
Apart from genome editing, the specific DNA binding capacity of catalytically inactive 
Cas9 has also led to many other applications in vitro and in vivo by fusion of different effectors. 
This has enabled site-specific applications such as gene regulation with transcriptional 
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effectors, modification of the epigenome by epigenetic modifiers and live cell chromatin 
imaging by fluorescent proteins59. In addition, CRISPR-based technologies have led to 
numerous other exciting applications, including in agriculture and healthcare, which are beyond 
the scope of this review76.  
 
Figure 2. Key developments in the history of genome editing.  
DSBs, double-strand breaks; HDR, homology-directed repair; KO, knock-out; PAM, protospacer 
adjacent motif; TALENs, transcription activator-like effector nucleases; ZFN, zinc finger nucleases. 
 
 
Conclusions and future directions 
 
Gene editing has revolutionized biomedical research. Starting from the realization that 
meganuclease-mediated DSBs enhance integration of foreign DNA, many researchers have 
searched for an optimal tool to introduce these breaks in the DNA in a sequence specific 
fashion. Protein engineering led to the use of programmable ZFNs and, shortly thereafter, 
TALENs, which soon paved the way to simple and robust RNA-guided CRISPR genome 
editing. Due to its superior applicability, CRISPR has quickly become routine in many 
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biomedical laboratories. Furthermore, the predominantly used and still most efficient SpCas9 
system has been re-engineered for higher specificity and widened range of targetable loci but 
also applications beyond genome editing. Additionally, many other CRISPR systems have been 
introduced for genome editing and even other applications.  
 Due to the high variability of bacteria and archaea, many other CRISPR systems are 
likely to be discovered in the future. These new variants hold great potential to overcome the 
current constraints of genome editing. The limitation of PAM availability is a common issue72. 
The discovery of new Cas proteins or intentional re-engineering of known variants without any 
PAM requirement but retained efficiency would simplify genome editing tremendously. 
Unintended mutations due to off-target effects are another main obstacle of current CRISPR 
systems used for genome editing77. Substantial efforts have already led to Cas9 variants with 
enhanced specificity and acceptable trade-off on efficacy. A high-fidelity Cas protein, natural 
or re-engineered, with retained efficiency has yet to be developed70. 
All genome editing tools only direct the endogenous repair machinery to a specific locus 
rather than directly inducing the desired genetic alteration. While off-target mutations can 
mostly be predicted due to a number of available algorithms, unintended alterations at the on-
target locus are still largely unpredictable. Besides small INDELs large and/or complex genetic 
alterations have been shown to occur including chromosomal translocations and megabase-
scale deletion78. Even newer generation tools aiming for high precision like prime and base 
editors are not entirely predictable in their outcome77. A consensus on criteria for quality control 
of genome edited animals will be essential in order to ensure reliable and reproducible research.  
Even if applied with rigid quality control to reduce the above-mentioned challenges, the 
number of animals needed per experiment will likely not be reduced compared to ES cell 
mutagenesis. Moreover, the ease of use and widespread availability of genome editing tools 
could even lead to an increase in genetically engineered models generated and accordingly 
animals used in research. However, the power of genome editing lies in its potential to introduce 
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mutations directly on desired genetic strain backgrounds and complex existing animal models. 
This largely avoids extensive animal breeding programs to obtain required allele configurations 
to an extent unachievable by classical genetic engineering. In addition, the ability for precise 
alteration of alleles will reflect human diseases more precisely than previously possible and in 
species most appropriate to the research objectives, ideally being less sentient than classical 
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